A systematic review and network meta-analysis of clinical trials found that several biologic and small-molecule therapies provided short-term improvement in adults with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin disease.
A pooled analysis of two phase 3 trials found that a once-daily topical anticholinergic gel significantly improved sweat reduction and symptom severity in patients with axillary hyperhidrosis, with a tolerable safety profile.
New research highlights strong associations between metabolic syndrome and several oral diseases—including periodontitis, caries, and peri-implantitis—calling for more longitudinal studies to explore causation and improve patient care.
Once used for coughs, ambroxol is being investigated for Parkinson disease dementia. A new trial shows it is safe and biologically active, though cognitive benefits remain unproven.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.